Stocks · News reference

RBC Capital Maintains Outperform on BeOne Medicines, Lowers Price Target to $450

Aug 6, 2026, 5:06 PMBenzinga Newsdesk

RBC Capital analyst Leonid Timashev maintains BeOne Medicines (NASDAQ:ONC) with a Outperform and lowers the price target from $451 to $450.

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Aug 6, 2026, 5:06 PM
Checked: Aug 6, 2026, 5:06 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaSep 1, 2026, 8:57 AMNamrata Sen
Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President
Trump secures drug pricing deals with nine pharma companies as Kennedy reveals intense pressure from the President to deliver.
ALC BBIO LLY NVO ONC
BenzingaAug 31, 2026, 7:44 PMBenzinga Newsdesk
Trump Administration Reaches New Drug Pricing Agreement With Nine Pharma Firms
BBIO ONC SPY TEVA
BenzingaAug 31, 2026, 7:07 PMBenzinga Newsdesk
BeOne Medicines Inks Voluntary Agreement With U.S. Government To Expand Access To Cancer Drugs For American Patients
ONC
BenzingaAug 31, 2026, 10:09 AMBenzinga Newsdesk
BeOne Medicines' Topline Data From Second Interim Analysis of Phase 3 HERIZON-GEA-01 Trial of ZIIHERA (zanidatamab) Plus Chemo, With and Without TEVIMBRA (tislelizumab) Show Statistically Significant and Clinically Meaningful Improvement in Overall Survival Trastuzumab Plus Chemo for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma
ONC